Latest news

• Merck completes €15m Spanish biotech facility expansion

  The Tres Cantos plant is Merck's main site for the production of active substances in its fertility treatment Gonal-f and endocrine and metabolic disorders treatment Saizen, for which global ... Merck was able to raise its sales forecast for 2016 earlier

• Fertility drugs drive healthcare growth at Merck KGaA

  Strong performances from Gonal-f and Rebif boost the firm’s 2016 sales forecast. ... In particular, the group's portfolio of fertility treatments put in a stellar performance, headed by Gonal-f which grew 23% to 209m.

• Roche and Merck boost manufacturing capacity

  for a number of Merck Serono drugs, including brands such as Gonal-f (follitropin-alfa) used to treat fertility. ... Gonal-f was its fastest-growing product, with sales up 11 per cent to 152m in the quarter.

• Sales down at Merck Serono on Rebif pressure

  Among its other products, sales of Merck Serono's fertility treatment Gonal-f (follitropin alfa) slipped fractionally to 137m while growth hormone Saizen (somatropin) brought in 61m, in line with one

• Merck KGaA to meet 2014 financial targets one year early

  This performance helped offset declines for other key brands, such as fertility treatment Gonal-f (follitropin alfa) and growth hormone product Saizen (somatropin), down 4 and 8 per cent to 145m